Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer

Pharmacogenomics

Volumn 15, Issue 12, 2014, Pages 1565-1574

  Lamba, Jatinder Kaur ^a,b   Fridley, Brooke L ^c   Ghosh, Taraswi M ^a   Yu, Qing ^c   Mehta, Gaurav ^d   Gupta, Pankaj ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d Minneapolis VA Healthcare System   (United States)

Author keywords

adverse effects; carboplatin; non small cell lung cancer; pharmacogenetics; prognosis; single nucleotide polymorphisms; taxane

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CISPLATIN; CREATININE; CYTOCHROME P450 2C8; ETOPOSIDE; GEMCITABINE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN P53; TAXANE DERIVATIVE; WILSON DISEASE PROTEIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; ABCB1 PROTEIN, HUMAN; BRIDGED COMPOUND; DNA BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TAXANE; TAXOID; XERODERMA PIGMENTOSUM GROUP F PROTEIN; XPC PROTEIN, HUMAN;

ABCB1 GENE; ABCC1 GENE; ABCG2 GENE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ATP7B GENE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER STAGING; CCDC127 GENE; CREATININE BLOOD LEVEL; CYP2C8 GENE; DIARRHEA; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ERCC4 GENE; FEBRILE NEUTROPENIA; GENE; GENETIC VARIABILITY; GENOTYPE; GTF2E1 GENE; HUMAN; KCNC1 GENE; KLC3 GENE; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NQO1 GENE; PHARMACOGENETICS; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TMEM63A GENE; TP53 GENE; VOMITING; XPC GENE; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION STUDY; GENETICS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRIDGED COMPOUNDS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NAD(P)H DEHYDROGENASE (QUINONE); NAUSEA; NEOPLASM STAGING; NEUTROPENIA; P-GLYCOPROTEINS; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; TAXOIDS; THROMBOCYTOPENIA;

EID: 84908122929     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.107     Document Type: Article

References (35)

1. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
2. SEER Stat Fact Sheets: Lung and Bronchus Cancer. http://seer.cancer.gov/statfacts/html/lungb.html
3. SEER Cancer Statistics Review, 1975-2010. http://seer.cancer.gov/csr/1975-2010
4. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol. 2, 694-705 (2007).
5. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-Agent or a 2-Agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-Analysis. JAMA 292, 470-484 (2004).
6. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33, 9-23 (2007).
7. Sprowl JA, Ness RA, Sparreboom A. Polymorphic transporters and platinum pharmacodynamics. Drug Metab. Pharmacokinet. 28, 19-27 (2013).
8. Lu C, Spitz MR, Zhao H, et al. Association between glutathione S-Transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 106, 441-447 (2006).
9. Okcu MF, Selvan M, Wang LE, et al. Glutathione S-Transferase polymorphisms and survival in primary malignant glioma. Clin. Cancer Res. 10, 2618-2625 (2004).
10. Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, et al. Glutathione S-Transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 11, 639-643 (2000).
11. Meijer C, Timmer A, De Vries EG, Groten JP, Knol A, et al. Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int. J. Cancer 85, 777-781 (2000).
12. Van Der Straaten T, Kweekel D, Tiller M, Bogaartz J, Guchelaar HJ. Multiplex pyrosequencing of two polymorphisms in DNA repair gene XRCC1. J. Mol. Diagn. 8, 444-448 (2006).
13. Sakano S, Wada T, Matsumoto H, et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br. J. Cancer 95, 561-570 (2006).
14. Wheeler HE, Gamazon ER, Stark AL, et al. Genome-wide meta-Analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 13, 35-43 (2013).
15. Marsh S, Paul J, King CR, et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J. Clin. Oncol. 25, 4528-4535 (2007).
16. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin. Cancer Res. 12, 854-859 (2006).
17. Kim HS, Kim MK, Chung HH, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol. Oncol. 113, 264-269 (2009).
18. PharmGKB. www.PharmGKB.org
19. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315, 525-528 (2007).
20. Caronia D, Patino-Garcia A, Perez-Martinez A, et al. Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS ONE 6, e26091 (2011).
21. Wu X, Gu J, Wu TT, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J. Clin. Oncol. 24, 3789-3798 (2006).
22. Siegel D, Yan C, Ross D. NAD(P)H: quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem. Pharmacol. 83, 1033-1040 (2012).
23. Traver RD, Siegel D, Beall HD, et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br. J. Cancer 75, 69-75 (1997).
24. Kolesar JM, Dahlberg SE, Marsh S, et al. The NQO12/2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncol. Rep. 25, 1765-1772 (2011).
25. Hertz DL, Motsinger-Reif AA, et al. CYP2C83 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res. Treat. 134, 401-410 (2012).
26. Bahadur N, Leathart JB, Mutch E, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem. Pharmacol. 64, 1579-1589 (2002).
27. Soyama A, Saito Y, Hanioka N, et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol. Pharm. Bull. 24, 1427-1430 (2001).
28. Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 1, 611-616 (2002).
29. Morisaki K, Robey RW, Ozvegy-Laczka C, et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother. Pharmacol. 56, 161-172 (2005).
30. Karachaliou N, Papadaki C, Lagoudaki E, et al. Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPOmicron-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide. PLoS ONE 8, e74611 (2013).
31. Vassalou H, Stathopoulos E, Fiolitaki G, et al. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. Lung Cancer 82, 324-329 (2013).
32. Xu TP, Shen H, Liu LX, Shu YQ. Association of ERCC1-C118T and-C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene 526, 265-274 (2013).
33. Caronia D, Patino-Garcia A, Milne RL, et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J. 9, 347-353 (2009).
34. Fernandez-Rozadilla C, Cazier JB, Moreno V, et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J. 13, 209-217 (2013).
35. Mazzoni F, Cecere FL, Meoni G, et al. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. Lung Cancer 82, 288-293 (2013).